AstraZeneca and Insitro: AI for MASH and Cardiomyopathies
AstraZeneca partners with the American company Insitro to apply artificial intelligence to the identification of therapeutic targets. The partnership, announced on October 15, 2026, focuses on two areas: MASH and cardiomyopathies.
Two Targeted Therapeutic Areas: MASH and Cardiomyopathies
The agreement concerns metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. MASH is a chronic liver disease, while cardiomyopathies affect the heart muscle. These two categories of pathologies define the initial scope of the collaboration.
Le brief IA que les pros lisent chaque soir
Les 7 actus IA du jour, décryptées en 5 min. Gratuit.
Inclus dès l'inscription : notre sélection des meilleurs guides & comparatifs IA.
Choisissez votre rythme
Gratuit · Pas de spam · Désabonnement en 1 clic
An AI Partnership Between a British and an American Company
On October 15, 2026, AstraZeneca, a UK-based pharmaceutical company, announced the signing of an agreement with Insitro, an American company specializing in treatment discovery through AI. This partnership aims to leverage artificial intelligence to optimize the identification of targets for new drugs in the areas covered by the agreement.
Brief IA — L'actualité IA en français
L'essentiel de l'actualité de l'intelligence artificielle, décrypté et expliqué chaque jour.